학술논문

Could soluble urokinase plasminogen receptor (suPAR) be used as a diagnostic biomarker for ventilator-associated pneumonia?
Document Type
Article
Source
Clinical Respiratory Journal. Nov2017, Vol. 11 Issue 6, p925-930. 6p.
Subject
*UROKINASE
*PLASMINOGEN activators
*VENTILATOR-associated pneumonia
*C-reactive protein
*CONTROL groups
Language
ISSN
1752-6981
Abstract
Background Soluble urokinase plasminogen activator receptor (suPAR) is a biomarker that is increasingly used for evaluation of systemic inflammation. This study was performed to investigate whether suPAR may possess a diagnostic value in patients with ventilator-associated pneumonia (VAP). Methods This clinical study was performed in the anesthesia intensive care units (ICUs) of our university. In addition to descriptive data, WBC, serum levels of C-reactive protein (CRP) and suPAR prior to and after development of VAP were noted and compared in 31 patients (22 men, 9 women) diagnosed with VAP (Study Group) and 19 patients without VAP (Control Group) in ICU (14 men, 5 women). Results The suPAR ( P = 0.023), CRP ( P = 0.037), WBCs ( P = 0.024) in patients with VAP were significantly higher than patients without VAP. There was no remarkable difference in terms of WBCs ( P = 0.052) and suPAR levels ( P = 0.616) between groups on the first day of connection to mechanical ventilator. The suPAR and CRP levels in patients with VAP were significantly higher than prior to development of VAP ( P = 0.001 for both). Area under curve value after diagnosis of pneumonia was found 0.248 ( P = 0.002). Conclusion To conclude, our results suggest that suPAR can be a useful diagnostic biomarker in patients with VAP. However, clinical trials on larger series are warranted to explore the clinical significance more accurately. [ABSTRACT FROM AUTHOR]